Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (868)	12/9/1998 9:54:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 965

FNS, Take a look at: cbs.marketwatch.com The reduced estimate, according to this, had nothing to do with the presumed hypersensitivity reaction. It is simply not true that any Remicade for arthritis studies have been stopped. The study that was halted was a re-treatment study of patients with Crohn's. There have been no reported reactions in people using Remicade for arthritis, perhaps because they are using the new formulation or because they are taking methotrexate. Peter